Almotriptan: a review of 20 years' clinical experience.

Abstract:

:Introduction: Almotriptan (ALT), a serotonin 5-HT1B/1D agonist has been used in the acute treatment of migraine with or without aura for 20 years, accumulating data on more than 15,000 patients in studies and from an estimated >150 million treated migraine attacks in daily clinical practice. The last major review of ALT was written almost 10 years ago. The current narrative review provides an overview of the experience gained with almotriptan over that time, and highlights data published in the last decade. Areas covered: Randomized clinical trials, observational studies, postmarketing studies and meta-analyses involving ALT for the treatment of acute migraine identified through a systematic literature search. Expert opinion: Triptans are a mainstay of anti-migraine treatment. Findings with ALT over the last 10 years have reinforced the positive efficacy and tolerability results that were reported during the first 10 years following its introduction. In particular, more recent clinical results have confirmed its efficacy in women with menstrual migraine, the usefulness of early intervention, long-term benefit in adults, and also its efficacy and safety in adolescents. Overall, ALT can be considered an optimal choice for managing acute migraine resistant to first-line drugs.

journal_name

Expert Rev Neurother

authors

Pascual J,Vila C

doi

10.1080/14737175.2019.1591951

subject

Has Abstract

pub_date

2019-08-01 00:00:00

pages

759-768

issue

8

eissn

1473-7175

issn

1744-8360

journal_volume

19

pub_type

杂志文章,评审
  • Management of von Hippel-Lindau disease-associated CNS lesions.

    abstract::Patients with von Hippel-Lindau disease (VHL) often harbor significant disease burden within the CNS, specifically craniospinal-axis hemangioblastomas and endolymphatic sac tumors (ELSTs). The majority (60-80%) of patients with VHL harbor hemangioblastomas, and 10-15% will develop ELSTs. Advances in the understanding ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.124

    authors: Wind JJ,Lonser RR

    更新日期:2011-10-01 00:00:00

  • Anaplastic astrocytomas: biology and treatment.

    abstract::Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms. Currently, the only factors that have been shown to influence prognosis in patients with AA are age and Karnofsky performance status. Attempts have been made to identify biological prognostic factors for response to therapy an...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.8.4.575

    authors: Chamberlain MC,Chowdhary SA,Glantz MJ

    更新日期:2008-04-01 00:00:00

  • Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment.

    abstract::The most successful approach for treating people with Alzheimer's disease to date has been by improving cholinergic transmission using cholinesterase inhibitors. Many of these drugs selectively inhibit acetylcholinesterase but some agents inhibit both acetylcholinesterase and butyrylcholinesterase. Recent evidence fro...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.5.1.101

    authors: Tasker A,Perry EK,Ballard CG

    更新日期:2005-01-01 00:00:00

  • Non-pharmacological interventions and neuroplasticity in early stage Alzheimer's disease.

    abstract::Non-pharmacological interventions have the potential to reduce cognitive decline and to improve psychosocial aspects in mild cognitive impairment and Alzheimer's dementia, and the absence of side effects makes them a favorable option also for preventive strategies. We provide an overview on recent studies involving co...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.845086

    authors: Herholz SC,Herholz RS,Herholz K

    更新日期:2013-11-01 00:00:00

  • The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.

    abstract::Irreversible disability is the critical long-term consequence of multiple sclerosis (MS). While there are well-established measures for disability in MS, they have limitations that may affect our perception of disease progression either due to the empirical nature of some assessments or the lack of validation with lon...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.869478

    authors: Kieseier BC

    更新日期:2014-01-01 00:00:00

  • Treatment of dystonia.

    abstract::Dystonia may be a sign or symptom, that is comprised of complex abnormal and dynamic movements of different etiologies. A specific cause is identified in approximately 28% of patients, which only occasionally results in specific treatment. In most cases, treatment is symptomatic and designed to relieve involuntary mov...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.6.863

    authors: Bhidayasiri R,Tarsy D

    更新日期:2006-06-01 00:00:00

  • Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.

    abstract::The need for maintenance therapy in patients with major depressive disorder (MDD) is underscored by the high likelihood of recurrence after short-term treatment. Current recommendations include treatment to remission and long-term treatment to prevent relapse and recurrence. This article will summarize the design and ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.5.737

    authors: Kornstein SG

    更新日期:2008-05-01 00:00:00

  • Gene therapy for Parkinson's disease.

    abstract::Advances in molecular biology and virology in recent years have enabled the technology of gene transfer to proceed forward. Parkinson's disease (PD) is a particularly appropriate target for gene therapy since the brain pathology is fully characterized and relatively well circumscribed largely within the nigrostriatal ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.8.957

    authors: Mochizuki H

    更新日期:2007-08-01 00:00:00

  • Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome.

    abstract::Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication. Rufinamide is a new antiepileptic drug approved as adjunctive therapy ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.51

    authors: Ferrie CD

    更新日期:2010-06-01 00:00:00

  • Electroconvulsive therapy in children and adolescents.

    abstract::Electroconvulsive therapy (ECT) is a recognized and effective treatment in adults for several psychiatric and neurological conditions in which the use of pharmacotherapy is ineffective, untimely or contraindicated. It has been used with success in mood and psychotic disorders, catatonia, neuroleptic malignant syndrome...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.178

    authors: Shoirah H,Hamoda HM

    更新日期:2011-01-01 00:00:00

  • Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision.

    abstract::With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.3.357

    authors: Bergamaschi R

    更新日期:2006-03-01 00:00:00

  • The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.

    abstract:INTRODUCTION:Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, str...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2018.1476140

    authors: Creese B,Da Silva MV,Johar I,Ballard C

    更新日期:2018-06-01 00:00:00

  • Deep brain stimulation for the treatment of uncommon tremor syndromes.

    abstract:INTRODUCTION:Deep brain stimulation (DBS) has become a standard therapy for the treatment of select cases of medication refractory essential tremor and Parkinson's disease however the effectiveness and long-term outcomes of DBS in other uncommon and complex tremor syndromes has not been well established. Traditionally,...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1194756

    authors: Ramirez-Zamora A,Okun MS

    更新日期:2016-08-01 00:00:00

  • Use of antiepileptic drugs in pregnancy.

    abstract::Babies born to mothers exposed to antiepileptic drugs (AEDs) are at increased risk for major congenital malformations, cognitive impairment and fetal death. For the millions of women with epilepsy, maintaining the safest drug that will successfully prevent seizures during pregnancy remains a primary consideration. The...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.7.1077

    authors: Tatum WO

    更新日期:2006-07-01 00:00:00

  • Teratogenic effects of antiepileptic drugs.

    abstract::Many antiepileptic drugs (AEDs) have therapeutic applications that extend beyond epilepsy to include neuropathic pain, migraine headaches and psychiatric disorders. The risk of some AEDs has been clearly established, but for newer drugs, small sample sizes and polytherapy exposures preclude a conclusive determination ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.57

    authors: Hill DS,Wlodarczyk BJ,Palacios AM,Finnell RH

    更新日期:2010-06-01 00:00:00

  • Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moon.

    abstract::In different study populations, several studies have shown that modest C-reactive protein elevation, in the range of apparently healthy individuals, is a strong predictor of future vascular events. Willcox and colleagues summarize the epidemiological and clinical observations that have led to the enthusiastic suggesti...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章,评审

    doi:10.1586/14737175.4.4.613

    authors: Di Napoli M,Papa F

    更新日期:2004-07-01 00:00:00

  • Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

    abstract::Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1028370

    authors: Rizzo R,Martino D

    更新日期:2015-04-01 00:00:00

  • The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis.

    abstract::The spectrum of idiopathic inflammatory-demyelinating disorders of the CNS is classified based on clinical symptoms and signs, clinical severity, lesion distribution, neuroimaging features and cerebrospinal fluid characteristics. There is a wide variety of conditions in this broad spectrum. In some cases, the dissemin...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.6

    authors: Idiman E,Ozakbaş S

    更新日期:2011-03-01 00:00:00

  • Triptanophobia in migraine: A case-control study on the causes and consequences of the nonuse of triptans in chronic migraine patients.

    abstract::Background: Triptanophobia is the excessive and inadequately justified concern about potential risks of triptans. We evaluated causes and consequences of nonuse of triptans in chronic migraine (CM) Methods: Case-control study. We included CM patients firstly referred to aheadache unit. Patients were cases or controls ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1842733

    authors: Martínez-Pías E,García-Azorín D,Minguez-Olaondo A,Trigo J,Sierra Á,Ruiz M,Guerrero ÁL

    更新日期:2021-01-01 00:00:00

  • Neuroprotection in primary brain tumors: sense or nonsense?

    abstract::Primary brain tumors are generally difficult to treat because of the unique location of the lesions. In addition, normal brain structures are often destroyed by the growing neoplasm. Even with effective therapy to surgically resect and destroy the neoplastic tissues, the brain is sometimes still injured, which can lea...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.5.723

    authors: Schaller BJ,Buchfelder M

    更新日期:2006-05-01 00:00:00

  • Special biological issues in the management of women with schizophrenia.

    abstract::Schizophrenia is a debilitating and pervasive mental illness with devastating effects on psychological, cognitive and social wellbeing, and for which current treatment options are far from ideal. Gender differences and the influence of the female reproductive life cycle on the onset, course and symptoms of schizophren...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.62

    authors: Kulkarni J,Gavrilidis E,Hayes E,Heaton V,Worsley R

    更新日期:2012-07-01 00:00:00

  • The need for emergency treatment of transient ischemic attack and minor stroke.

    abstract::The risk of recurrent stroke following transient ischemic attack or minor stroke has recently been shown to be 5-10% at 1 week and 10-20% at 3 months, depending on study population and methods. This is considerably higher than previously estimated and current clinical guidelines reflect the need for rapid assessment a...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.2.203

    authors: Giles MF,Rothwell PM

    更新日期:2005-03-01 00:00:00

  • Cluster headache mechanism and treatment.

    abstract::There have been remarkable strides in the last decade in unraveling the mystery of primary headache disorders, such as migraine and cluster headache. The vascular theory has been superseded by the neurovascular phenomena which seems to be the permissive triggering factor in migraine and cluster headache. This has been...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.5.713

    authors: Aurora S

    更新日期:2003-09-01 00:00:00

  • Duloxetine in the acute and continuation treatment of major depressive disorder.

    abstract::Duloxetine is a serotonin-noradrenaline reuptake inhibitor with indications for use in the short term, continuation and maintenance treatment of major depression. Although clinicians currently have access to a range of medications for the treatment of depression, a significant number of patients fail to respond or rem...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/ern.11.133

    authors: Bochsler L,Olver JS,Norman TR

    更新日期:2011-11-01 00:00:00

  • Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting.

    abstract::Background: Relatively little is known about the use of disease-modifying drugs (DMDs) for multiple sclerosis (MS) in the population-based universal healthcare setting. This study aimed to describe the characteristics of a population-based cohort with MS and their DMD exposure in four Canadian provinces. Methods: We i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1847085

    authors: Ng HS,Zhu F,Kingwell E,Zhao Y,Yao S,Ekuma O,Svenson LW,Evans C,Fisk JD,Marrie RA,Tremlett H

    更新日期:2021-01-01 00:00:00

  • Depression and randomized, controlled trials: problems and solutions.

    abstract::Research into what works in depression is in trouble. All treatments appear equally effective and what happens in research trials does not seem to translate into clinical practice or, to put it another way, clinical practice is not reflected in randomized controlled trials. We run the risk of designing cosmetic trials...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.1.41

    authors: Hatcher S

    更新日期:2006-01-01 00:00:00

  • Fentanyl for breakthrough pain: a systematic review.

    abstract::The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.63

    authors: Davis MP

    更新日期:2011-08-01 00:00:00

  • Electrophysiologic and immunopathologic correlates in Guillain-Barré syndrome subtypes.

    abstract::Guillain-Barré syndrome (GBS) includes demyelinating and axonal subtypes with different immunopathologic mechanisms. In acute inflammatory demyelinating polyradiculoneuropathy, segmental demyelination and conduction block are the pathological and electrophysiological correlates of muscle weakness. Slowed conductions a...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.43

    authors: Uncini A,Yuki N

    更新日期:2009-06-01 00:00:00

  • The search for biomarkers in Parkinson's disease: a critical review.

    abstract::Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily presents with features of bradykinesia, rigidity and tremor, and has, as part of its core pathology, the degeneration of dopaminergic neurons in the substantia nigra pars compacta. There is a great need for the development of a reliabl...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.12.1841

    authors: Antoniades CA,Barker RA

    更新日期:2008-12-01 00:00:00

  • Acute ischemic stroke management: concepts and controversies.A narrative review.

    abstract:INTRODUCTION:Amongst the 25.7 million survivors and 6.5 million deaths from stroke between 1990 and 2013, ischemic strokes accounted for approximately 70% and 50% of the cases, respectively. With patients still suffering from complications and stroke recurrence, more questions have been raised as to how we can better i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1836963

    authors: Li KHC,Jesuthasan A,Kui C,Davies R,Tse G,Lip GYH

    更新日期:2021-01-01 00:00:00